After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
The company said that given recent debt restructuring efforts and certain regulatory and payor approvals of its products, it's on track for a strong 2017.
In Nucleic Acids Research this week: isomiR-based cancer classifier, map of VjbR binding in Brucella, and more.
The developers said such a signature could help triage people exposed to radiation through war, a terrorist attack, or an industrial accident.
In Science this week: DNA Fountain for storing data in DNA, and more.
The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.
Investigators explored computational strategies for identifying microRNAs that are most relevant to tumor development and progression.
In PLOS this week: ramifications of multi-nucleotide de novo mutations, circulating microRNAs and atrial fibrillation, and more.
The partners aim to identify a microRNA-based signature that can predict lung cancer patient response to Bristol-Myers Squibb's immunotherapy Opdivo.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.